CHD2 Antibody

What is CHD2 and why is it important in research?

CHD2 is a DNA-binding helicase protein that belongs to the SNF2/RAD54 helicase family. It specifically binds to the promoters of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3 . The canonical human CHD2 protein consists of 1828 amino acid residues with a molecular mass of 211.3 kDa and is primarily localized in the nucleus .

CHD2 is a critical player in:

• Embryonic development

• Hematopoiesis (blood cell formation)

• Tumor suppression

• DNA damage response

• Genome stability maintenance

Research has shown that CHD2 heterozygous mutant mice exhibit increased extra-medullary hematopoiesis and susceptibility to lymphomas, highlighting its importance in disease models .

What applications are CHD2 antibodies suitable for?

CHD2 antibodies are versatile tools applicable to multiple experimental techniques:

Note: Antibody performance may vary between suppliers and applications. It's recommended to validate each antibody for your specific experimental conditions .

How do I properly store and handle CHD2 antibodies?

For optimal performance and longevity of CHD2 antibodies:

• Store at -20°C for long-term storage

• Antibodies are typically stable for one year after shipment when properly stored

• Many CHD2 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is generally unnecessary for -20°C storage but may be beneficial for frequently used antibodies to prevent freeze-thaw cycles

• Some smaller size formats (e.g., 20μl) may contain 0.1% BSA as a stabilizer

When handling the antibody:

• Avoid repeated freeze-thaw cycles

• Centrifuge briefly before opening to collect solution at the bottom of the tube

• Work with clean pipette tips and sterile technique to prevent contamination

How do CHD2 antibodies help in investigating chromatin remodeling mechanisms?

CHD2 functions as a critical chromatin remodeler that influences gene expression through several mechanisms:

• Nucleosome positioning: CHD2 uses energy from ATP hydrolysis to change nucleosome positioning and composition, directly affecting chromatin structure and accessibility .

• Histone H3.3 deposition: Research shows CHD2 enhances deposition of the variant histone H3.3, which is associated with hyperdynamic chromatin enrichment at promoters of genes that regulate cell-type specific developmental programs .

• Transcription factor cooperation: CHD2 co-binds the genome with transcription factors such as NKX2.1 during specification of human embryonic stem cells (hESCs) to medial ganglionic eminence-like progenitors (hMGEs) and during differentiation into human cortical interneurons (hcINs) .

When designing experiments to study these mechanisms:

• Use CHD2 antibodies for ChIP-seq to identify genome-wide binding profiles

• Combine with RNA-seq to correlate binding with gene expression changes

• Perform co-immunoprecipitation to identify protein-protein interactions with transcriptional machinery

Research has revealed that CHD2 binding patterns change significantly during cellular differentiation, with studies identifying 42,707 binding peaks in hESCs compared to 19,626 in hMGEs and 17,737 in hcINs .

What are the common technical challenges when working with CHD2 antibodies in Western blotting?

Western blotting for CHD2 presents several technical challenges:

• Variable molecular weight detection: While the calculated molecular weight of CHD2 is 211 kDa, antibodies may detect bands at different sizes:

  • Some antibodies detect CHD2 at 230-250 kDa

  • Others consistently detect it around 95 kDa

  • This variability may be due to:

    • Alternative splicing (3 different isoforms reported)

    • Post-translational modifications

    • Proteolytic processing

• Optimization recommendations:

  • Use gradient gels (4-12%) for better resolution of high molecular weight proteins

  • Extend transfer time for large proteins (>200 kDa)

  • Include protease inhibitors in lysis buffers to prevent degradation

  • Consider positive controls using CHD2-overexpressing cells

  • Test multiple antibodies targeting different epitopes

• Validation approaches:

  • Compare results with CHD2 knockout or knockdown samples

  • Verify specificity using peptide competition assays

  • If detecting unexpected band sizes, confirm with orthogonal methods (IP-MS)

Recent research demonstrates consistent detection of CHD2 at the undifferentiated stage around 95 kDa, suggesting stage-specific expression patterns important for gene regulation .

How can researchers use CHD2 antibodies to investigate its role in DNA damage response?

CHD2 is implicated in DNA damage response pathways, making antibodies valuable tools for studying genome stability:

• DNA damage foci analysis:

  • CHD2 mutant mice show defective hematopoietic stem cell differentiation and accumulate higher levels of γH2AX (a chromatin-associated DNA damage response mediator)

  • Use dual immunofluorescence with anti-CHD2 and anti-γH2AX antibodies to study co-localization at DNA damage sites

  • Quantify changes in foci number/intensity after DNA damaging treatments (X-ray irradiation, genotoxic drugs)

• Chromatin dynamics assessment:

  • CHD2 affects genomic stability by regulating DNA damage responses at the chromatin level

  • CHD2 can influence DNA repair by increasing nucleosome spacing and interacting with PARP1, potentially via promoting H3.3 incorporation into nucleosomes

  • Use CHD2 antibodies in combination with chromatin fractionation to track CHD2 recruitment to damaged chromatin

• Cell cycle-dependent localization:

  • Research in Xenopus models has shown that CHD2 localizes to microtubules of the mitotic spindle

  • Pathological variants in CHD2 cause disruption in localization at the microtubule with cell cycle stalling, leading to DNA damage and cell death

  • Use immunofluorescence with cell cycle markers to track CHD2 localization throughout the cell cycle

This makes CHD2 antibodies crucial tools for investigating both chromatin-dependent and potentially microtubule-dependent aspects of genome stability maintenance.

How do I optimize CHD2 antibody dilutions for different experimental applications?

Determining the optimal antibody dilution is critical for generating specific and reproducible results:

For systematic optimization:

• Western blot titration:

  • Load equal amounts of positive control lysate across multiple lanes

  • Apply different antibody dilutions to each strip

  • Select the dilution that provides clean, specific signal with minimal background

• IHC optimization:

  • Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • Evaluate multiple antibody incubation times (overnight at 4°C vs. 1-2 hours at room temperature)

  • Include appropriate blocking steps to reduce non-specific binding

• Cross-validation:

  • Verify results using multiple antibodies targeting different epitopes of CHD2

  • Include genetic knockdown/knockout controls when possible

It's recommended that each antibody should be titrated in each testing system to obtain optimal results as sample type can significantly impact performance .

What are the most effective validation strategies for confirming CHD2 antibody specificity?

Rigorous validation is essential for ensuring antibody specificity and reproducible results:

• Genetic approaches:

  • Test antibody reactivity in CHD2 knockout/knockdown models

  • Use CHD2 heterozygous (Chd2WT/m) and homozygous (Chd2m/m) mutant samples showing expected ~50% and ~75% reduction in CHD2 levels in whole brain lysates

  • Compare results in cells overexpressing CHD2 versus control cells

• Biochemical validation:

  • Peptide competition assays to confirm epitope specificity

  • Cross-reactivity assessment across species (human, mouse, rat samples)

  • Mass spectrometry validation of immunoprecipitated material

• Orthogonal techniques:

  • Correlation between protein detection (Western blot) and mRNA expression (qRT-PCR)

  • Compare results from antibodies targeting different epitopes

  • Use complementary immunodetection methods (e.g., IF and WB)

Research suggests special care when validating CHD2 antibodies as some CHD2-/- models still show measurable protein on Western blot, which could lead to misinterpretation of results .

How can I investigate CHD2's role in tissue-specific contexts using immunohistochemistry?

CHD2 expression varies across tissues, making IHC a valuable approach for studying its tissue-specific functions:

• Tissue selection guidance:

  • Expression analysis of Chd2 transcripts in wild-type adult mice showed highest expression in thymus, followed by lungs, kidneys, spleen, heart, testis, and liver

  • This expression pattern correlates with the observation that Chd2 mutant mice develop lymphomas, suggesting tissue-specific functions

• Optimization for different tissues:

  • For lymphoid tissues: Use human lymphoma tissue as positive control

  • For neural tissues: Use rat brain tissue with TE buffer pH 9.0 for antigen retrieval

  • For reproductive tissues: Mouse testis tissue has shown consistent results

• Co-localization studies:

  • Combine CHD2 IHC with markers of cell proliferation (Ki-67) to assess correlation with replicating cells

  • Use dual staining with cell-type specific markers to identify CHD2-expressing populations

  • For CNS tissues, co-stain with neuronal markers to investigate CHD2's role in neurodevelopmental disorders

• Pathological considerations:

  • Chd2 heterozygous mice exhibit increased numbers of activated CD44high CD4 T cells in mice with hyperplasia or lymphomas

  • These findings suggest examining T cell populations may be particularly informative when studying CHD2-related pathologies

When interpreting results, consider that CHD2's highest expression in thymus provides evidence for the tissue-specific induction of lymphomas in Chd2 mutants .

How are CHD2 antibodies being used to understand neurodevelopmental disorders?

CHD2 has emerged as an important factor in neurodevelopment, with mutations linked to several disorders:

• Pathogenic mechanisms:

  • Most pathological variants in CHD2 lead to protein truncation

  • Pathogenic missense variants tend to occur in the highly conserved DNA-binding or helicase domains, which likely hinders CHD2's ability to remodel chromatin

  • CHD2 haploinsufficiency can cause increased expression of many neuronal genes, potentially leading to autism and other neurodevelopmental disorders

• Research applications:

  • CHD2 antibodies are essential for studying protein localization and abundance in neuronal tissues

  • IHC and IF allow visualization of CHD2 expression patterns in developing brain regions

  • Chromatin immunoprecipitation with CHD2 antibodies helps identify direct target genes during neuronal development

• Model systems:

  • Use antibodies to validate CHD2 expression in human embryonic stem cells and their differentiation to cortical interneurons

  • Xenopus models have shown CHD2 localizes to microtubules, suggesting non-canonical functions that may be relevant to neurodevelopment

  • CHD2's role in human cortical interneuron development makes it a valuable target for understanding developmental disorders

Recent studies have used CHD2 antibodies to track its genome-wide binding profile during neuronal differentiation, showing significant changes in binding patterns across developmental stages that correlate with gene expression changes .

What are the considerations when using CHD2 antibodies in chromatin immunoprecipitation (ChIP) experiments?

ChIP experiments with CHD2 antibodies provide valuable insights into its genome-wide binding patterns:

• Antibody selection criteria:

  • Choose antibodies validated specifically for ChIP applications

  • Consider antibodies targeting different domains to capture various CHD2 binding contexts

  • Verify specificity using ChIP-qPCR at known target regions before proceeding to genome-wide analyses

• Experimental design considerations:

  • Appropriate crosslinking conditions (typically 1% formaldehyde for 10 minutes)

  • Sonication parameters must be optimized to achieve 200-500 bp DNA fragments

  • Include appropriate controls (IgG, input)

  • Consider sequential ChIP (ChIP-reChIP) to identify co-occupancy with other factors

• Data interpretation guidance:

  • CHD2 binding patterns change significantly during cellular differentiation

  • In hESCs to hcIN differentiation, CHD2 showed 42,707 binding peaks in hESCs compared to 19,626 in hMGEs and 17,737 in hcINs

  • Almost half of all hESC peaks (26,980) were unique to this time point, with 10,946 peaks shared between all three cell states

  • CHD2 binding correlates with expression changes of associated genes during differentiation

• Advanced applications:

  • Combine CHD2 ChIP-seq with other epigenetic marks (H3K4me3, H3K27ac) to understand regulatory contexts

  • Integrate with transcription factor binding site (TFBS) analysis to identify co-regulatory partners

  • CHD2-bound genes in different cell states show enrichment for distinct transcription factor motifs, suggesting stage-specific co-regulatory mechanisms

These findings demonstrate that CHD2 may work with a range of transcription factors known to regulate neuronal development or specifically cortical interneurons .

How can researchers investigate the interplay between CHD2 and histone variants using specialized antibody techniques?

CHD2's role in depositing histone variants, particularly H3.3, represents an important aspect of its function:

• Combined immunoprecipitation approaches:

  • Sequential ChIP (first with anti-CHD2, then with anti-H3.3 antibodies) to identify genomic regions where both co-occur

  • Co-IP experiments to confirm physical interaction between CHD2 and histone chaperones involved in H3.3 deposition

  • Proximity ligation assays (PLA) to visualize and quantify CHD2-H3.3 interactions in situ

• Functional assessment strategies:

  • CHD2 has been shown to enhance deposition of histone H3.3, which is associated with hyperdynamic chromatin enrichment at promoters of genes regulating cell-type specific developmental programs

  • Use CHD2 antibodies in combination with H3.3 antibodies to track changes in H3.3 incorporation at CHD2 target sites following CHD2 depletion

  • Examine H3.3 turnover rates at CHD2-bound regions using SNAP-tagged H3.3 and pulse-chase experiments

• Genomic context analysis:

  • H3.3 is generally associated with poised or active histone modifications

  • Combine CHD2 ChIP-seq with ChIP-seq for various histone modifications (H3K4me3, H3K27ac, H3K36me3) to understand the chromatin landscape at CHD2-bound regions

  • Assess the impact of CHD2 depletion on histone modification patterns at its target genes

This research direction is particularly relevant as CHD2 has been shown to be involved in myogenesis via interaction with MYOD1: it binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression .

How can CHD2 antibodies be utilized in cancer research and potential therapeutic development?

CHD2's role in tumor suppression makes it an important target in cancer research:

• Expression analysis in tumors:

  • Chd2 heterozygous mutant mice exhibit increased susceptibility to lymphomas

  • Use CHD2 antibodies for IHC to compare expression levels between normal and tumor tissues

  • Quantitative analysis of CHD2 in tissue microarrays to correlate expression with clinical outcomes

• Functional studies in cancer models:

  • Chd2 mutants show defects in hematopoietic stem cell differentiation and accumulate higher levels of γH2AX

  • Use CHD2 antibodies to assess its interaction with DNA repair machinery in cancer cell lines

  • Investigate CHD2's potential role in DNA damage response pathways commonly dysregulated in cancer

• Therapeutic implications:

  • The highest expression of Chd2 in the thymus provides evidence for tissue-specific induction of lymphomas in the Chd2 mutants

  • This suggests potential tissue-specific therapeutic approaches targeting CHD2-related pathways

  • CHD2 antibodies can help identify downstream effectors that might represent more druggable targets

• Biomarker potential:

  • Evaluate CHD2 as a potential biomarker for treatment response, particularly to DNA damaging therapies

  • Use antibodies to develop immunoassays for detecting CHD2 levels in patient samples

Recent initiatives like the "Roadmap to Cure CHD2" highlight the growing interest in therapeutic approaches for CHD2-related disorders, where antibodies play a crucial role in validating disease mechanisms and therapeutic targets .

What methods can researchers use to study CHD2 protein-protein interactions in different cellular contexts?

Understanding CHD2's interactome is crucial for deciphering its multiple functions:

• Co-immunoprecipitation strategies:

  • Use CHD2 antibodies for pull-down experiments followed by mass spectrometry

  • Reciprocal IPs with antibodies against suspected interacting partners

  • Comparison of interactomes across different cell types or developmental stages

• Proximity-based approaches:

  • BioID or APEX2 proximity labeling with CHD2 fusion proteins

  • Validation of proximity hits using co-IP with CHD2 antibodies

  • Proximity ligation assays (PLA) for visualizing interactions in situ

• Domain-specific interactions:

  • Use antibodies targeting specific domains of CHD2 to identify domain-specific binding partners

  • Create domain deletion constructs and use antibodies to assess impact on interaction networks

  • CHD2 has been shown to interact with various transcription factors including NKX2.1 , suggesting context-specific regulatory partners

• Functional validation:

  • CHD2 interacts with PARP1 during DNA damage response

  • CHD2 binds with MYOD1 during myogenesis

  • Use antibodies to track these interactions under different cellular conditions or following stimuli

Research in Xenopus models has revealed that CHD2 localizes to microtubules of the mitotic spindle , suggesting potential interactions with cytoskeletal proteins that could be further investigated using CHD2 antibodies in co-localization studies.